Literature DB >> 15193403

Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle.

Catherine D Jepson1, John B March.   

Abstract

The stability of whole bacteriophage lambda particles, used as a DNA vaccine delivery system has been examined. Phage were found to be highly stable under normal storage conditions. In liquid suspension, no decrease in titre was observed over a 6-month period at 4 and -70 degrees C, and phage stability was unaffected by freeze/thawing. The measured half life of phage in suspension was 36 days at 20 degrees C, 3.4 days at 37 degrees C and 2.3 days at 42 degrees C. Freeze drying of a phage suspension (with or without the stabilizers dry skim milk or trehalose) resulted in 5-20% residual viability. Following desiccation (with or without stabilizers), measured half lives ranged from 20 to 100 days at 20 degrees C, 2.6 to 38 days at 37 degrees C, 2.1 to 26 days at 42 degrees C, 7 to 33 h at 70 degrees C, and 1.3 to 6m at 100 degrees C. In all cases the addition of trehalose significantly increased the stability of the desiccated phage. When stored at -70 degrees C, desiccated phage appeared to be stable in the absence of stabilizers. When phage lambda was diluted into water, a marginal loss in titre was observed over a 2-week period. Over a 24 h period, liquid phage suspensions were stable within the pH range pH 3-11, therefore oral administration of bacteriophage DNA vaccines via drinking water may be possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193403     DOI: 10.1016/j.vaccine.2003.11.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

Review 1.  Biological gene delivery vehicles: beyond viral vectors.

Authors:  Yiqi Seow; Matthew J Wood
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

2.  Phage library screening for the rapid identification and in vivo testing of candidate genes for a DNA vaccine against Mycoplasma mycoides subsp. mycoides small colony biotype.

Authors:  John B March; Catherine D Jepson; Jason R Clark; Makrina Totsika; Michael J Calcutt
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery.

Authors:  Yongsheng Ma; Jennifer C Pacan; Qi Wang; Yongping Xu; Xiaoqing Huang; Anton Korenevsky; Parviz M Sabour
Journal:  Appl Environ Microbiol       Date:  2008-05-30       Impact factor: 4.792

4.  Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.

Authors:  Atefeh Saeedi; Amir Ghaemi; Alijan Tabarraei; Abdolvahab Moradi; Ali Gorji; Shahryar Semnani; Hoorieh Soleimanjahi; Ahmad Hosseinzadeh Adli; Seyed Yones Hosseini; Mohammad Ali Vakili
Journal:  Virus Genes       Date:  2014-04-22       Impact factor: 2.332

5.  Influence of some environmental variables and addition of r-lysozyme on efficacy of Vibrio harveyi phage for therapy.

Authors:  Tanmoy Gon Choudhury; Biswajit Maiti; M N Venugopal; Indrani Karunasagar
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

6.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

Review 7.  Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine.

Authors:  Kegan S Sunderland; Mingying Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2017-01-24       Impact factor: 15.336

Review 8.  Bacteriophages and medical oncology: targeted gene therapy of cancer.

Authors:  Babak Bakhshinejad; Marzieh Karimi; Majid Sadeghizadeh
Journal:  Med Oncol       Date:  2014-07-11       Impact factor: 3.064

9.  Recombinant lambda-phage nanobioparticles for tumor therapy in mice models.

Authors:  Amir Ghaemi; Hoorieh Soleimanjahi; Pooria Gill; Zuhair Hassan; Soodeh Razeghi M Jahromi; Farzin Roohvand
Journal:  Genet Vaccines Ther       Date:  2010-05-12

10.  Unauthorized horizontal spread in the laboratory environment: the tactics of Lula, a temperate lambdoid bacteriophage of Escherichia coli.

Authors:  Ella Rotman; Luciana Amado; Andrei Kuzminov
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.